Shattuck Labs, Inc. (NASDAQ:STTK) Receives $6.20 Average Price Target from Analysts

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have earned a consensus recommendation of “Hold” from the seven analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $6.20.

A number of brokerages have weighed in on STTK. HC Wainwright raised shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a research report on Thursday, January 22nd. Citigroup upped their price objective on Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a report on Tuesday, January 6th. Finally, Piper Sandler started coverage on Shattuck Labs in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 target price for the company.

Shattuck Labs Price Performance

Shattuck Labs stock opened at $3.86 on Thursday. Shattuck Labs has a 12 month low of $0.69 and a 12 month high of $4.89. The company has a market cap of $244.26 million, a PE ratio of -3.78 and a beta of 1.52. The company has a fifty day moving average price of $3.82 and a two-hundred day moving average price of $2.48.

Institutional Trading of Shattuck Labs

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd acquired a new position in Shattuck Labs in the second quarter valued at approximately $98,000. Pinnacle Associates Ltd. raised its position in shares of Shattuck Labs by 4.9% during the 2nd quarter. Pinnacle Associates Ltd. now owns 1,363,723 shares of the company’s stock valued at $1,080,000 after acquiring an additional 64,000 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Shattuck Labs during the 2nd quarter valued at $44,000. AQR Capital Management LLC lifted its stake in shares of Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after purchasing an additional 31,355 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Shattuck Labs in the 3rd quarter worth $38,000. 58.74% of the stock is owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.